FDA approves seizure disorder treatment
ROCKVILLE, Md. The Food and Drug Administration has approved a new drug for treating seizure disorders.
The FDA announced Friday the approval of Sabril (vigabatrin) oral solution, made by Deerfield, Ill.-based Lundbeck. The drug is approved for treating infantile spasms in children ages 1 month to 2 years and is the first drug approved in the United States to treat the disorder.
The agency also approved Sabril tablets as a treatment for epileptic seizures in adults.
“Seizures can cause impaired nervous system function and reduced quality of life,” FDA Center for Drug Evaluation and Research Division of Neurology Products director Russell Katz said in a statement. “Infantile spasms in children this young are very serious, and this approval provides these patients and their parents a treatment option.”
Infantile spasms typically appear between the ages of 4 months and 8 months and can cause bending forward of the body, arching of the back and stiffening of the limbs. The spasms tend to occur after awakening or after feeding and can happen in clusters of up to 100.
The FDA said Sabril would carry a boxed warning, the agency’s strongest warning label, to alert healthcare professionals of the risk of permanent vision damage.
Stiefel zaps acne segment with ‘leave-on’ treatment
DULUTH, Ga. Stiefel Labs, a GlaxoSmithKline company, launched one of the first “leave-on” treatments for acne care, PanOxyl, as a line extension to the company’s acne-care bar and wash.
The formulation is not greasy as compared with spot treatments, and blends into the skin upon application. The new formulation delivers 10% Benzoyl Peroxide in a foam delivery.
In addition to consumer ad support, Stiefel will be fielding its 200-strong dedicated representatives to detail dermatologists.
Stiefel also introduced its Sensitive Sarna eczema itch relief kit, an all-in-one kit that includes a cleanse, itch relief and moisturizer.
New directors elected to NACDS Foundation board
ALEXANDRIA, Va. The National Association of Chain Drug Stores has elected three new directors to the board of the NACDS Foundation.
Jim VanLieshout, VP retail sales with Apotex; Alice Swearingen, VP channel development sales for GlaxoSmithKline; and Chris Dimos, president of pharmacy operations for Supervalu, will fill vacancies on the board, which consists of 22 members.
“We are pleased to welcome the three new members to the NACDS Foundation board of directors,” said Edith Rosato, president of the NACDS Foundation.
“They will continue the strong representation on the board of chains and suppliers alike. We value their expertise, dedication and commitment to the industry, and we look forward to working together for the good of the public and the patients served by community pharmacy.”